nanosynth group provides an update on JV agreement with Volz

nanosynth Group plc (LON:NNN) has announced that further to the announcement of the Joint Venture Agreement with inter alia, Volz Holdings v.o.s on 10 December 2021, agreement has been reached for Volz to convert their production line to provide the capability for nanosynth’s alphaviron layer to be included across Volz’s product range. This is extremely beneficial to the JV Company, Virosynth Limited, as Volz are not only a HVAC material provider but also an HVAC filter provider. This means that by Volz converting their production line to incorporate the Company’s technology as standard, Virosynth will end up with its first client, with leading edge advantage in the marketplace and a great reference point for others to see and follow due to the benefits Virosynth can deliver for the HVAC market and the reputation Volz holds in the market.

This is also expected to save Virosynth considerable cash expenditure.

The cost of converting the Volz production line is considerable. It has therefore been agreed that to save nanosynth having to inject cash into Virosynth to meet half the cost of this, it will instead provide a warrant over ordinary shares in the Company to the shareholders of Volz, namely; Rainer Volz and Jonathan Thornton.

Accordingly, the Company has issued £500,000 of warrants over 50,000,000 shares at an exercise price of 1 pence each (a premium of c.29% to the closing mid market share price on 9 February 2022) to be granted equally to Rainer Volz and Jonathan Thornton. The Warrants are exercisable for a period of three years from the date of grant and only upon completion of the conversion of the product line.

Related Party Transaction

Jonathan Thornton, as a director of Virosynth, which is a 51% owned subsidiary of the Company, is considered to be a “related party” as defined under the AIM Rules and accordingly the grant of Warrants constitutes a related party transaction for the purposes of Rule 13 of the AIM Rules.

Mark Duffin, Richard Clarke, Dr Felicity Sartain and Dr Gareth Cave, being the Directors independent of the transaction, consider, having consulted with SP Angel Corporate Finance LLP, the Company’s Nominated Adviser, that the grant of the Warrants are fair and reasonable insofar as the Company’s shareholders are concerned.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Nanosynth Group plc

    More articles like this

    Nanosynth Group plc

    Nanotechnology in cosmetics and cosmeceuticals

    Nanoparticles (NPs) are defined as materials with dimensions smaller than 100 nm and presenting various shapes, i.e., spheres, rods, dendritic shapes, etc. This definition is accepted by the European Union (EU) Commission. It should be noted, however,

    Nanosynth Group plc

    Nanoparticles in cosmetics

    Nanoparticles are particles that are smaller than 100 nanometer (1/10,000 millimeter) which is about 40,000 times thinner than a hair. There are two forms of nanoparticles: soluble and biodegradable nanoemulsions such as liposomes and insoluble nanopigments

    Nanosynth Group plc

    What nanoparticles do to our cells

    During the past few years, nanoparticles have been increasingly present in our everyday lives. To gain a better understanding of their health impacts, several studies have focused on the effects they have on our bodies and

    Nanosynth Group plc

    Role of nanotechnology for design and development of cosmeceutical

    Nanotechnology is an innovative area of science that includes the design, characterization, production, and application of materials, devices and systems by controlling shape and size at the nanometer scale (1–100 nm). Nanotechnology incorporation in cosmetic formulation

    Nanosynth Group plc

    Nanotech could be the next frontier of drug delivery

    Nanotechnology is an emerging and rapidly developing area in the pharmaceutical and medicinal field. For example, nanoparticles can be used as drug delivery systems. Nanotechnology could help overcome the limitations of conventional drug delivery such as biodistribution and

    Nanosynth Group plc

    Nanoparticles to aid cancer treatments

    Conventional therapies in cancer treatment face challenges in delivery of drugs in the body and just the quantity needed, due to the toxic nature of the medicines used that have unwanted side effects. Nanomaterials have ‘enormous’

    Nanosynth Group plc

    Nanoparticles: Emerging trends in human health and environment

    As part of the ongoing Govt of India initiative “Azadi ka Amrit Mahatosav”, the Indian Journal of Biochemistry and Biophysics (IJBB), CSIR-National Institute of Science Communication and Policy Research (NIScPR), New Delhi, has brought out its

    Nanosynth Group plc

    Nanoparticles that self-assemble inside cells to fight cancer

    Inspired by viral replication, researchers developed a therapy that commandeers biological processes to craft nanoparticles within macrophages to aid in cancer therapy. Through self-assembly, the nanoparticles address some of the delivery issues plaguing present renditions of nanomedicines,

    Nanosynth Group plc

    nanosynth Group getting a huge amount of traction (LON:NNN)

    nanosynth’s Mark Duffin discusses what the company does, the Volz trial results, joint venture with a global wellness company and what investors can expect for the rest of the year in this exclusive interview with DirectorsTalk.

    Nanosynth Group plc

    Nanotechnology in the nutricosmetics industry

    Nanotechnology for Nutricosmetics Nanocarriers are ubiquitous within nanomedicine; however, with skin quality and health in high demand for consumers, these fields have overlapped. The use of nanotechnology and nanoformulations as delivery systems for improving the performance

    Nanosynth Group plc

    Nanotechnology in cosmetics

    Nanotechnology is the science of manipulating atoms and molecules in the nanoscale – 80,000 times smaller than the width of a human hair. The world market for products that contain nanomaterials is expected to reach $2.6